

Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Michel Dib, et al

Examiner: Not Yet Assigned

Application No.: **10/783,451**

Art Unit: 1614

Filed: **February 20, 2004**

Title: **Combination Of Cyamemazine And An
Atypical, Neuroleptic**

I hereby certify that this correspondence is being deposited with
the United States Postal Service as First Class Mail in an envelope
addressed to Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

8/4/04
Date of Deposit
Mark Q Meads
Signature



INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


The items listed with an asterisk on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series:

ST99053 US CNT, Serial No. 10/164,771, filed June 07, 2002.

Therefore, copies of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,

August 4, 2004


Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Aventis Docket No. **ST99053 US CNT 1**

☒

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Complete if Known

(use as many sheets as necessary)

3

ST99053 - US - CNT - 1

[illegible]

Examiner Initials ⁷	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	*	EP	0196132		KENNIS	10-01-1986		
	*	EP	0200322		PERREGAARD	11-05-1986		
	*	EP	0392959		PERREGAARD	10-17-1990		
	*	EP	0454436		CHAKRABARTL, ET AL	10-30-1991		
	*	EP	0529500		BARTLETT	08-19-1992		
	*	EP	0586191		DOUGLAS, ET AL	03-09-1994		
	*	EP	0733634		BUNNELL	09-25-1996		
	*	FR	2722099		SAUVEUR	01-12-1996		
	*	WO	94/25460		MESENS	11-10-1994		
	*	WO	96/30375		BUNNELL, ET AL	10-03-1996		

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/783,451
				Filing Date	02-20-2004
				First Named Inventor	MICHEL DIB
				Group Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	ST99053 - US - CNT - 1

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/783,451	
			Filing Date	02-20-2004	
			First Named Inventor	MICHEL DIB	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	ST99053 - US - CNT - 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	*	DIETCH, James T. et al., Aggressive Dyscontrol in Patients Treated with Benzodiazepines, J. Clin Psychiatry (1988, pp. 184-188, Volume 49:5)	
	*	OVERALL, John E. et al., The Brief Psychiatric Rating Scale, Psychological Reports, (1962, pp. 799-812, Volume 10)	
	*	SENNINGER, J. L. et al., La Risperidone Dans Le Traitement de L' Agressivite Des Schizophrenes, Ann. Med. Psychol. (1998, pp. 210-213, Volume 156 No. 3)	
	*	STIMMEL, Glen L., Benzodiazepines in Schizophrenia, Supplement to Pharmacotherapy (1996, pp. 148-151, Volume 16)	
	*	Vandel, et al, Drug extrapyramidal side effects, Eur. J. Clin. Pharmacol. (1999, pp. 659-665, Volume 55, No. 9)	
	*	WARNEKE, Lorne B., Benzodiazepines: Abuse and New Use, Can. J. Psychiatry (1991, pp. 194-205, Volume 36)	
	*	WOLKOWITZ, Owen M. et al., Benzodiazepines in the Treatment of Schizophrenia; A Review and Reappraisal, Am J Psychiatry (1991), pp. 714-726, Volume 148:6)	
	*	ZINI, R et al., The Influence of Various Drugs on the Binding of Tianeptine to Human Plasma Proteins, International Journal of Clinical Pharmacology, Therapy and Toxicology (1991, pp. 64-66, Volume 29 No. 2)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.